Inicio
Resultado de la búsqueda
4 búsqueda de la palabra clave 'Ulcerative colitis'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Clinical differentiation of inflammatory bowel disease (IBD) in Latin America and the Caribbean / Fabián Juliao Baños
Título : Clinical differentiation of inflammatory bowel disease (IBD) in Latin America and the Caribbean Tipo de documento : documento electrónico Autores : Fabián Juliao Baños, Fecha de publicación : 2022 Títulos uniformes : Medicine (Baltimore) Idioma : Inglés (eng) Palabras clave : Crohn disease epidemiology inflammatory bowel disease Latin America ulcerative colitis Resumen : The aim of the present study was to describe the epidemiological and clinical characteristics of inflammatory bowel disease (IBD), including medical and surgical treatments, in several countries in Latin America and the Caribbean. IBD is recognized as a global health problem because its incidence and prevalence have increased significantly over the last few years. This multicenter retrospective cohort study included 4714 patients with IBD diagnosed from 9 countries in Latin America and the Caribbean: Colombia, Cuba, Dominican Republic, Ecuador, Mexico, Peru, Puerto Rico, Uruguay, and Venezuela. Crohn disease (CD) was more frequent in Puerto Rico (71.9%), the Dominican Republic (61.0%), and Peru (53.1%). Ulcerative colitis was more frequent in Colombia (78.6%), Venezuela (78.2%), Mexico (75.5%), Cuba (69.9%), Ecuador (64.1%), and Uruguay (60.9%). The following clinical characteristics were more frequent in the Caribbean: penetrating behavior in CD, steroid dependence, steroid resistance, intolerance to thiopurines, extraintestinal manifestations, surgeries, hospitalizations due to IBD, and family history of IBD. The factors associated with the use of biological therapy were pancolitis in ulcerative colitis, penetrating behavior in CD, steroid resistance and dependence, presence of extraintestinal manifestations, and the need for surgery. This study from Latin America and the Caribbean demonstrated the different epidemiological and clinical characteristics of IBD. Mención de responsabilidad : Yamamoto-Furusho, Jesús K. MD, PhD, MSc; Parra-Holguín, Norma N. MD; Juliao-Baños, Fabián MD; Puentes, Fabián MD; López, Rocio MD; Bosques-Padilla, Francisco MD; Torres, Esther A. MD; Nieves-Jimenéz, Humberto MD; Veitia-Velásquez, Guillermo R. MD; Jara-Alba, Maria L. MD; Bautista, Sócrates MD; Piñol-Jimenez, Felipe N. MD; Salgado-Rosado, Pablo MD; Villa-Ovalle, Keyla C. MD; Abreu-Martinez, Yudelka A. MD; Borges, Zunilda MD; Davila-Bedoya, Santiago MD; Otoya-Moreno, Guillermo MD; Iadé-Vergara, Beatriz MD Referencia : Medicine (Baltimore). 2022 Jan 21;101(3):e28624. DOI (Digital Object Identifier) : 10.1097/MD.0000000000028624 PMID : 35060539 Derechos de uso : CC BY En línea : https://journals.lww.com/md-journal/Fulltext/2022/01210/Clinical_differentiation [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Clinical differentiation of inflammatory bowel disease (IBD) in Latin America and the Caribbean [documento electrónico] / Fabián Juliao Baños, . - 2022.
Obra : Medicine (Baltimore)
Idioma : Inglés (eng)
Palabras clave : Crohn disease epidemiology inflammatory bowel disease Latin America ulcerative colitis Resumen : The aim of the present study was to describe the epidemiological and clinical characteristics of inflammatory bowel disease (IBD), including medical and surgical treatments, in several countries in Latin America and the Caribbean. IBD is recognized as a global health problem because its incidence and prevalence have increased significantly over the last few years. This multicenter retrospective cohort study included 4714 patients with IBD diagnosed from 9 countries in Latin America and the Caribbean: Colombia, Cuba, Dominican Republic, Ecuador, Mexico, Peru, Puerto Rico, Uruguay, and Venezuela. Crohn disease (CD) was more frequent in Puerto Rico (71.9%), the Dominican Republic (61.0%), and Peru (53.1%). Ulcerative colitis was more frequent in Colombia (78.6%), Venezuela (78.2%), Mexico (75.5%), Cuba (69.9%), Ecuador (64.1%), and Uruguay (60.9%). The following clinical characteristics were more frequent in the Caribbean: penetrating behavior in CD, steroid dependence, steroid resistance, intolerance to thiopurines, extraintestinal manifestations, surgeries, hospitalizations due to IBD, and family history of IBD. The factors associated with the use of biological therapy were pancolitis in ulcerative colitis, penetrating behavior in CD, steroid resistance and dependence, presence of extraintestinal manifestations, and the need for surgery. This study from Latin America and the Caribbean demonstrated the different epidemiological and clinical characteristics of IBD. Mención de responsabilidad : Yamamoto-Furusho, Jesús K. MD, PhD, MSc; Parra-Holguín, Norma N. MD; Juliao-Baños, Fabián MD; Puentes, Fabián MD; López, Rocio MD; Bosques-Padilla, Francisco MD; Torres, Esther A. MD; Nieves-Jimenéz, Humberto MD; Veitia-Velásquez, Guillermo R. MD; Jara-Alba, Maria L. MD; Bautista, Sócrates MD; Piñol-Jimenez, Felipe N. MD; Salgado-Rosado, Pablo MD; Villa-Ovalle, Keyla C. MD; Abreu-Martinez, Yudelka A. MD; Borges, Zunilda MD; Davila-Bedoya, Santiago MD; Otoya-Moreno, Guillermo MD; Iadé-Vergara, Beatriz MD Referencia : Medicine (Baltimore). 2022 Jan 21;101(3):e28624. DOI (Digital Object Identifier) : 10.1097/MD.0000000000028624 PMID : 35060539 Derechos de uso : CC BY En línea : https://journals.lww.com/md-journal/Fulltext/2022/01210/Clinical_differentiation [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001945 AC-2022-106 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2022-106.pdfAdobe Acrobat PDF
Título : Global hospitalization trends for Crohn's disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses Tipo de documento : documento electrónico Autores : Fabián Juliao Baños, Fecha de publicación : 2022 Títulos uniformes : Clinical Gastroenterology and Hepatology Idioma : Inglés (eng) Palabras clave : Inflammatory Bowel Disease Crohn’s Disease Ulcerative Colitis Hospitalization Rates Epidemiology Resumen : Background & Aims: The evolving epidemiologic patterns of inflammatory bowel disease (IBD) throughout the world, in conjunction with advances in therapeutic treatments, may influence hospitalization rates of IBD. We performed a systematic review with temporal analysis of hospitalization rates for IBD across the world in the 21st century. Methods: We systematically reviewed Medline and Embase for population-based studies reporting hospitalization rates for IBD, Crohn’s disease (CD), or ulcerative colitis (UC) in the 21st century. Log-linear models were used to calculate the average annual percentage change (AAPC) with associated 95% confidence intervals (95% CIs). Random-effects meta-analysis pooled country-level AAPCs. Data were stratified by the epidemiologic stage of a region: compounding prevalence (stage 3) in North America, Western Europe, and Oceania vs acceleration of incidence (stage 2) in Asia, Eastern Europe, and Latin America vs emergence (stage 1) in developing countries. Results: Hospitalization rates for a primary diagnosis of IBD were stable in countries in stage 3 (AAPC, −0.13%; 95% CI, −0.72 to 0.97), CD (AAPC, 0.20%; 95% CI, −1.78 to 2.17), and UC (AAPC, 0.02%; 95% CI, −0.91 to 0.94). In contrast, hospitalization rates for a primary diagnosis were increasing in countries in stage 2 for IBD (AAPC, 4.44%; 95% CI, 2.75 to 6.14), CD (AAPC, 8.34%; 95% CI, 4.38 to 12.29), and UC (AAPC, 3.90; 95% CI, 1.29 to 6.52). No population-based studies were available for developing regions in stage 1 (emergence). Conclusions: Hospitalization rates for IBD are stabilizing in countries in stage 3, whereas newly industrialized countries in stage 2 have rapidly increasing hospitalization rates, contributing to an increasing burden on global health care systems. Mención de responsabilidad : Michael J. Buie, Joshua Quan, Joseph W. Windsor, Stephanie Coward, Tawnya M. Hansen, James A. King, Paulo G. Kotze, Richard B. Gearry, Siew C. Ng, Joyce W.Y. Mak, Maria T. Abreu, David T. Rubin, Charles N. Bernstein, Rupa Banerjee, Jesus K. Yamamoto-Furusho, Remo Panaccione, Cynthia H. Seow, Christopher Ma, Fox E. Underwood, Vineet Ahuja, Nicola Panaccione, Abdel-Aziz Shaheen, Jayna Holroyd-Leduc, Gilaad G. Kaplan, Domingo Balderramo, Vui Heng Chong, Fabián Juliao-Baños, Usha Dutta, Marcellus Simadibrata, Jamilya Kaibullayeva, Yang Sun, Ida Hilmi, Raja Affendi Raja Ali, Mukesh Sharma Paudel, Mansour Altuwaijri, Juanda Leo Hartono, Shu Chen Wei, Julajak Limsrivilai, Sara El Ouali, Beatriz Iade Vergara, Viet Hang Dao, Paul Kelly, Phoebe Hodges, Yinglei Miao y Maojuan Li Referencia : Clin Gastroenterol Hepatol. 2022 Jul 19;S1542-3565(22)00670-X. DOI (Digital Object Identifier) : 10.1016/j.cgh.2022.06.030 PMID : 35863682 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S154235652200670X Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Global hospitalization trends for Crohn's disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses [documento electrónico] / Fabián Juliao Baños, . - 2022.
Obra : Clinical Gastroenterology and Hepatology
Idioma : Inglés (eng)
Palabras clave : Inflammatory Bowel Disease Crohn’s Disease Ulcerative Colitis Hospitalization Rates Epidemiology Resumen : Background & Aims: The evolving epidemiologic patterns of inflammatory bowel disease (IBD) throughout the world, in conjunction with advances in therapeutic treatments, may influence hospitalization rates of IBD. We performed a systematic review with temporal analysis of hospitalization rates for IBD across the world in the 21st century. Methods: We systematically reviewed Medline and Embase for population-based studies reporting hospitalization rates for IBD, Crohn’s disease (CD), or ulcerative colitis (UC) in the 21st century. Log-linear models were used to calculate the average annual percentage change (AAPC) with associated 95% confidence intervals (95% CIs). Random-effects meta-analysis pooled country-level AAPCs. Data were stratified by the epidemiologic stage of a region: compounding prevalence (stage 3) in North America, Western Europe, and Oceania vs acceleration of incidence (stage 2) in Asia, Eastern Europe, and Latin America vs emergence (stage 1) in developing countries. Results: Hospitalization rates for a primary diagnosis of IBD were stable in countries in stage 3 (AAPC, −0.13%; 95% CI, −0.72 to 0.97), CD (AAPC, 0.20%; 95% CI, −1.78 to 2.17), and UC (AAPC, 0.02%; 95% CI, −0.91 to 0.94). In contrast, hospitalization rates for a primary diagnosis were increasing in countries in stage 2 for IBD (AAPC, 4.44%; 95% CI, 2.75 to 6.14), CD (AAPC, 8.34%; 95% CI, 4.38 to 12.29), and UC (AAPC, 3.90; 95% CI, 1.29 to 6.52). No population-based studies were available for developing regions in stage 1 (emergence). Conclusions: Hospitalization rates for IBD are stabilizing in countries in stage 3, whereas newly industrialized countries in stage 2 have rapidly increasing hospitalization rates, contributing to an increasing burden on global health care systems. Mención de responsabilidad : Michael J. Buie, Joshua Quan, Joseph W. Windsor, Stephanie Coward, Tawnya M. Hansen, James A. King, Paulo G. Kotze, Richard B. Gearry, Siew C. Ng, Joyce W.Y. Mak, Maria T. Abreu, David T. Rubin, Charles N. Bernstein, Rupa Banerjee, Jesus K. Yamamoto-Furusho, Remo Panaccione, Cynthia H. Seow, Christopher Ma, Fox E. Underwood, Vineet Ahuja, Nicola Panaccione, Abdel-Aziz Shaheen, Jayna Holroyd-Leduc, Gilaad G. Kaplan, Domingo Balderramo, Vui Heng Chong, Fabián Juliao-Baños, Usha Dutta, Marcellus Simadibrata, Jamilya Kaibullayeva, Yang Sun, Ida Hilmi, Raja Affendi Raja Ali, Mukesh Sharma Paudel, Mansour Altuwaijri, Juanda Leo Hartono, Shu Chen Wei, Julajak Limsrivilai, Sara El Ouali, Beatriz Iade Vergara, Viet Hang Dao, Paul Kelly, Phoebe Hodges, Yinglei Miao y Maojuan Li Referencia : Clin Gastroenterol Hepatol. 2022 Jul 19;S1542-3565(22)00670-X. DOI (Digital Object Identifier) : 10.1016/j.cgh.2022.06.030 PMID : 35863682 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S154235652200670X Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001954 AC-2022-115 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-115Adobe Acrobat PDF
Título : Trends in the epidemiology of inflammatory bowel disease in Colombia by demographics and region using a nationally representative claims database and characterization of inflammatory bowel disease phenotype in a case series of Colombian patients Tipo de documento : documento electrónico Autores : Fabián Juliao Baños, ; Jorge Hernando Donado Gómez, Fecha de publicación : 2021 Títulos uniformes : Medicine (Baltimore) Idioma : Inglés (eng) Palabras clave : Colombians Crohn’s disease Epidemiology Hispanics Latinos Ulcerative colitis Resumen : The incidence of inflammatory bowel disease (IBD) is on the rise in Latin America. The aims of this study were to examine epidemiologic trends of IBD in Colombia by demographics, region, urbanicity, and to describe the IBD phenotype in a large well-characterized Colombian cohort. We used a national database of 33 million adults encompassing 97.6% of the Colombian population in order to obtain epidemiologic trends of IBD using International Classification of Diseases 10codes for adults with ulcerative colitis (UC) and Crohn disease (CD). We calculated the incidence and prevalence of UC and CD from 2010–2017 and examined epidemiologic trends by urbanicity, demographics, and region. We then examined the IBD phenotype (using Montreal Classification), prevalence of IBD-related surgeries, and types of IBD-medications prescribed to adult patients attending a regional IBD clinic in Medellin, Colombia between 2001 and 2017. The incidence of UC increased from 5.59/100,000 in 2010 to 6.3/100,000 in 2017 (relative risk [RR] 1.12, confidence interval (CI) (1.09–1.18), P Mención de responsabilidad : Juliao-Baños, Fabian MD; Kock, Joshua MD, MSc; Arrubla, Mateo MD; Calixto, Omar MD; Camargo, Joselyn MD; Cruz, Lina MD; Hurtado, Juan MD; Clavijo, Absalon MD; Donado, Jorge MD, MSc; Schwartz, Seth PhD; Abreu, Maria T. MD; Damas, Oriana M. MD Referencia : Medicine (Baltimore). 2021 Feb 19;100(7):e24729. DOI (Digital Object Identifier) : 10.1097/MD.0000000000024729 PMID : 33607817 Derechos de uso : CC BY-NC En línea : https://journals.lww.com/md-journal/Fulltext/2021/02190/Trends_in_the_epidemiolo [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Trends in the epidemiology of inflammatory bowel disease in Colombia by demographics and region using a nationally representative claims database and characterization of inflammatory bowel disease phenotype in a case series of Colombian patients [documento electrónico] / Fabián Juliao Baños, ; Jorge Hernando Donado Gómez, . - 2021.
Obra : Medicine (Baltimore)
Idioma : Inglés (eng)
Palabras clave : Colombians Crohn’s disease Epidemiology Hispanics Latinos Ulcerative colitis Resumen : The incidence of inflammatory bowel disease (IBD) is on the rise in Latin America. The aims of this study were to examine epidemiologic trends of IBD in Colombia by demographics, region, urbanicity, and to describe the IBD phenotype in a large well-characterized Colombian cohort. We used a national database of 33 million adults encompassing 97.6% of the Colombian population in order to obtain epidemiologic trends of IBD using International Classification of Diseases 10codes for adults with ulcerative colitis (UC) and Crohn disease (CD). We calculated the incidence and prevalence of UC and CD from 2010–2017 and examined epidemiologic trends by urbanicity, demographics, and region. We then examined the IBD phenotype (using Montreal Classification), prevalence of IBD-related surgeries, and types of IBD-medications prescribed to adult patients attending a regional IBD clinic in Medellin, Colombia between 2001 and 2017. The incidence of UC increased from 5.59/100,000 in 2010 to 6.3/100,000 in 2017 (relative risk [RR] 1.12, confidence interval (CI) (1.09–1.18), P Mención de responsabilidad : Juliao-Baños, Fabian MD; Kock, Joshua MD, MSc; Arrubla, Mateo MD; Calixto, Omar MD; Camargo, Joselyn MD; Cruz, Lina MD; Hurtado, Juan MD; Clavijo, Absalon MD; Donado, Jorge MD, MSc; Schwartz, Seth PhD; Abreu, Maria T. MD; Damas, Oriana M. MD Referencia : Medicine (Baltimore). 2021 Feb 19;100(7):e24729. DOI (Digital Object Identifier) : 10.1097/MD.0000000000024729 PMID : 33607817 Derechos de uso : CC BY-NC En línea : https://journals.lww.com/md-journal/Fulltext/2021/02190/Trends_in_the_epidemiolo [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001680 AC-2021-011 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2021-011Adobe Acrobat PDF
Título : Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population Tipo de documento : documento electrónico Autores : Fabián Juliao Baños, ; Natalia Aristizábal Henao, ; Carlos Enrique Yepes Delgado, ; Julio Eduardo Zuleta Muñoz, Fecha de publicación : 2013 Títulos uniformes : Digestion Idioma : Inglés (eng) Palabras clave : Ulcerative colitis infliximab tumor necrosis factor α- Anti-tumor necrosis factor α Resumen : Background: Previous research has shown that infliximab (IFX) is effective in the management of moderate to severe active ulcerative colitis (UC). Latin American studies are lacking. Aim: To evaluate the efficacy of IFX treatment (including corticosteroid withdrawal, complete mucosal healing, colectomy and hospitalization rates) in patients with moderate to severe UC. Methods: A retrospective and descriptive study was conducted on patients with UC in Medellín (Colombia). We included patients steroid dependent or refractory to conventional treatment. Results: Between October 2005 and July 2011, 28 patients with moderate to severe UC received IFX infusions; the median of the follow-up was 27.4 months (range: 1-69 months). Twenty-four patients (86%) had a short-term primary response, whilst 19 (68%) achieved initial clinical remission. After 1 year, 17 (71%) out of the 24 patients who had an initial response were also showing a sustained response, and 10 (42%) remained in clinical remission. At 6 months, complete mucosal healing was observed in 29% of patients and endoscopic improvement in 57%. Conclusions: This is the first study to evaluate the IFX use in patients with moderate to severe active UC in a Latin American population. We found that IFX therapy is effective for inducing clinical remission, and that most patients who had an initial response showed a long-term sustained response. Mención de responsabilidad : Fabian Juliao, Juan Marquez, Natalia Aristizabal, Carlos Yepes, Julio Zuleta, Javier P Gisbert Referencia : Digestion. 2013;88(4):222-8. DOI (Digital Object Identifier) : 10.1159/000355529 PMID : 24281150 En línea : https://www.karger.com/Article/Abstract/355529 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population [documento electrónico] / Fabián Juliao Baños, ; Natalia Aristizábal Henao, ; Carlos Enrique Yepes Delgado, ; Julio Eduardo Zuleta Muñoz, . - 2013.
Obra : Digestion
Idioma : Inglés (eng)
Palabras clave : Ulcerative colitis infliximab tumor necrosis factor α- Anti-tumor necrosis factor α Resumen : Background: Previous research has shown that infliximab (IFX) is effective in the management of moderate to severe active ulcerative colitis (UC). Latin American studies are lacking. Aim: To evaluate the efficacy of IFX treatment (including corticosteroid withdrawal, complete mucosal healing, colectomy and hospitalization rates) in patients with moderate to severe UC. Methods: A retrospective and descriptive study was conducted on patients with UC in Medellín (Colombia). We included patients steroid dependent or refractory to conventional treatment. Results: Between October 2005 and July 2011, 28 patients with moderate to severe UC received IFX infusions; the median of the follow-up was 27.4 months (range: 1-69 months). Twenty-four patients (86%) had a short-term primary response, whilst 19 (68%) achieved initial clinical remission. After 1 year, 17 (71%) out of the 24 patients who had an initial response were also showing a sustained response, and 10 (42%) remained in clinical remission. At 6 months, complete mucosal healing was observed in 29% of patients and endoscopic improvement in 57%. Conclusions: This is the first study to evaluate the IFX use in patients with moderate to severe active UC in a Latin American population. We found that IFX therapy is effective for inducing clinical remission, and that most patients who had an initial response showed a long-term sustained response. Mención de responsabilidad : Fabian Juliao, Juan Marquez, Natalia Aristizabal, Carlos Yepes, Julio Zuleta, Javier P Gisbert Referencia : Digestion. 2013;88(4):222-8. DOI (Digital Object Identifier) : 10.1159/000355529 PMID : 24281150 En línea : https://www.karger.com/Article/Abstract/355529 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000325 AC-2013-093 Archivo digital Producción Científica Artículos científicos Disponible
